SBP 9881
Alternative Names: SBP-9881Latest Information Update: 28 Jul 2024
Price :
$50 *
At a glance
- Originator Sanford Burnham Prebys Medical Discovery Institute
- Developer Sanford Burnham Prebys Medical Discovery Institute; University of California, San Diego
- Class Antidepressants; Small molecules
- Mechanism of Action Metabotropic glutamate receptor 2 modulators; Metabotropic glutamate receptor 3 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Depressive disorders; Major depressive disorder
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Depressive disorders(Treatment-resistant) in USA (PO)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Major depressive disorder in USA (PO)
- 30 Jun 2020 Camino Pharma receives SBIR grant from National Institute of Mental Health for development of SBP 9881 for Major depressive disorders and Depressive disorders (Treatment-resistant)